Thermo launches next-generation, compressor-free plate sealer

28 Jan 2020

Features new functionalities and capabilities making it versatile for a variety of both manual and automated microplate processing life science applications.

Thermo Fisher Scientific has launched its next-generation, compressor-free plate sealer, designed to alleviate the maintenance burden on operators, while offering unparalleled process customization capabilities, intuitive operation and significant work efficiencies.

Thermo launches next-generation, compressor-free plate sealer
The Thermo Scientific ALPS 5000 Plate Sealer.

Biotechnology, pharmaceutical and academic research laboratories can now benefit from a system capable of simplifying the plate sealing process and enabling improved reliability and productivity for both stand-alone, as well as, integrated robotic projects.

As a fully electrically operated system, the Thermo Scientific ALPS 5000 has been developed to increase the efficiency of the heat plate sealing process and offers maximum flexibility to support high-throughput applications. The system eliminates the need for tedious and costly replacement of expensive vacuum cups, onboard compressors and compressed air lines, typically required when using conventional pneumatically driven equipment. As a result, maintenance costs are minimized and quieter operation is enabled ensuring minimal disruption to the working environment. Designed as one of the most user-friendly units available on the market, the ALPS 5000 facilitates easy, tool-free foil loading and does not require the use of adapters to change between different plates. The system is operated via a large intuitive touchscreen with a modern user interface, which allows for precise control over sealing parameters to ensure repeatability, while including programming parameters for integration into automation or robotic workflows.

The ALPS 5000 offers superior process customization capabilities to address varying application needs, from polymerase chain reaction and high-performance liquid chromatography to next-generation sequencing, compound storage and flow cytometry. Users can program the sealing time, temperature and pressure parameters to suit their specific requirements. They can also choose the most appropriate sealing foil length, opting for a longer foil to improve pealing or a shorter one to reduce foil usage by up to 10%. Moreover, the ALPS 5000 offers the flexibility to use either a traditional force sealing, or a distance sealing to maximize the number of times a plate can be resealed.

"Reliable plate sealing is essential to researchers who wish to avoid unnecessary experiment repeats and data inconsistency due to sample contamination and evaporation," explains Sung Dae Hong, vice president and general manager for laboratory plastics essentials at Thermo Fisher Scientific. "With storage requirements and laboratory processes becoming increasingly complicated, scientists and researchers are looking for solutions that can simplify their day-to-day operations and meet their specific application needs. Our new ALPS 5000 Plate Sealer has been developed to do just that, streamlining the plate sealing process, improving reproducibility and minimizing maintenance requirements, while preserving precious research."

The ALPS 5000 offers fast sealing times, being able to seal up to four plates per minute. It also features a compact footprint to save valuable bench space. Furthermore, the ALPS 5000 has been equipped with an Eco Mode, which triggers a temperature reduction down to 30C° when the system has been inactive for a pre-specified amount of time, allowing for considerable energy savings.

Read More

Related news

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

21 Feb 2020

Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.

Read more 
Catalent to manufacture first-in-class mAb targeting solid tumours

Catalent to manufacture first-in-class mAb targeting solid tumours

11 Feb 2020

ZM008 could have potential benefits for the treatment of prostate cancer.

Read more 
BD completes clinical trial for its wearable injector

BD completes clinical trial for its wearable injector

11 Feb 2020

The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.

Read more 
New Velesco Pharma clinical manufacturing facility begins operations

New Velesco Pharma clinical manufacturing facility begins operations

5 Feb 2020

The facility will triple the company’s cGMP clinical trial manufacturing capacity.

Read more 
Inovio and Beijing Advaccine to advance vaccine against Coronavirus

Inovio and Beijing Advaccine to advance vaccine against Coronavirus

30 Jan 2020

Agreement will facilitate clinical trial translations in China.

Read more 
First human trial of monoclonal antibody to prevent malaria opens

First human trial of monoclonal antibody to prevent malaria opens

28 Jan 2020

If proven safe and effective, mAb CIS43LS might be used prophylactically by tourists, medical workers or military personnel who travel to areas where malaria is common.

Read more 
Merck invests in biotech development facility in Switzerland

Merck invests in biotech development facility in Switzerland

27 Jan 2020

€250 million to be invested during the 2019-2022 period in new facility bridging research and manufacturing.

Read more 
Grey Wolf Therapeutics secures funding for cancer therapies development

Grey Wolf Therapeutics secures funding for cancer therapies development

21 Jan 2020

The company targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system.

Read more 
Diabetes diagnosis - now a matter of sweat and tears?

Diabetes diagnosis - now a matter of sweat and tears?

21 Jan 2020

No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.

Read more 
BioMarin gets go-ahead to start gene therapy clinical trials

BioMarin gets go-ahead to start gene therapy clinical trials

15 Jan 2020

BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.

Read more